ArticleVirus genes2008
Enhanced immune response of DNA vaccine (VP1-pCDNA) adsorbed on cationic PLG for foot and mouth disease in guinea pigs.
Article in Virus genes, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 6 citations in OpenAlex.
- Molecular Mechanisms of Immune Escape for Foot-and-Mouth Disease Virus.Pathogens (Basel, Switzerland) · 2020Review
- Protective effect of recombinant staphylococcal enterotoxin A entrapped in polylactic-co-glycolic acid microspheres against Staphylococcus aureus infection.Veterinary research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Foot and mouth disease (FMD) is the major constraint to international trade in livestock and animal products. Though conventional vaccine has shown to provide protection, it has several limitations, like short duration of immunity and poor cell mediated immune response compared to DNA vaccines, which are known to induce both cell mediated as well as humoral responses. The present work envisages the production of DNA vaccine construct with partial 1D gene (coding for VP1) of FMDV type 'A' and studied the efficacy of the vaccine coated on cationic PLGA micro-particles in guinea pigs. Sequence coding for VP1 of serotype 'A' was amplified by PCR and cloned into mammalian expression vector, pCDNA-containing FMDV IRES. Expression of the construct was confirmed by transfection of the plasmid into BHK-21 cells followed by the protein profile by SDS-PAGE and Western blotting of the cell lysate. Guinea pigs were immunized with 25 mug of the vaccine construct intramuscularly, followed by a booster at 21st day. Sera from the animals of all the groups (pre-vaccinated, 14, 21, and 28 days of post-vaccination) was analyzed by ELISA and SNT. ELISA titers indicated significant improvement in the antibody titers in the PLG-coated DNA group (2.408 + 0.06), whereas the naked plasmid gave a titer of 1.505+. Serum neutralization titers were higher in PLG-coated vaccine group compared to the animals that received the naked DNA vaccine. Increased CTL response measured by MTT stimulation index (1.58 + 0.08) was observed in the case of PLG-coated DNA vaccine construct compared to the naked DNA vaccine (1.29 + 0.068). PLG-DNA vaccine construct conferred 100% protection to the animals when challenged with 100GpID50 of homologous virus compared to 50% protection in case of naked DNA vaccine construct. The present study has shown that adjuvantation with PLG markedly improved the efficacy of DNA vaccine against FMDV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.